EMA Recommends Extension of Therapeutic Indications for Retifanlimab By Ogkologos - February 6, 2026 405 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with squamous cell carcinoma of the anal canal Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR 2021 ASCO Annual Meeting Research Round Up: Advances in Genitourinary Cancers June 23, 2021 PFS Benefit in Patients with Metastatic Breast Cancer Receiving Matched Treatments... October 11, 2022 Combination of Immunotherapy Drugs Approved for Metastatic Colorectal Cancer August 3, 2018 Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers July 7, 2026 Load more HOT NEWS FDA Oversight of E-Cigarettes Gathers Speed: A Conversation with Mitch Zeller EMA Recommends Granting a Conditional Marketing Authorisation for Talquetamab Relugolix Approval Expected to Alter Treatment for Advanced Prostate Cancer Bus Driver Wears Different Costume Each Day To Make Kids Smile...
